Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVO NASDAQ:PLTR NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$49.49+1.2%$45.39$35.12▼$71.79$220.96B0.7719.09 million shs6.31 million shsPLTRPalantir Technologies$126.79-1.7%$132.81$106.37▼$207.52$303.95B1.5647.38 million shs31.09 million shsUTHRUnited Therapeutics$547.06-1.0%$557.18$272.12▼$609.35$23.22B0.58492,988 shs301,306 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S+0.14%-2.89%+15.91%+30.43%-29.90%PLTRPalantir Technologies-2.41%-0.20%-2.29%+0.81%-9.84%UTHRUnited Therapeutics-0.34%-0.62%-0.12%-3.37%+83.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$49.49+1.2%$45.39$35.12▼$71.79$220.96B0.7719.09 million shs6.31 million shsPLTRPalantir Technologies$126.79-1.7%$132.81$106.37▼$207.52$303.95B1.5647.38 million shs31.09 million shsUTHRUnited Therapeutics$547.06-1.0%$557.18$272.12▼$609.35$23.22B0.58492,988 shs301,306 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S+0.14%-2.89%+15.91%+30.43%-29.90%PLTRPalantir Technologies-2.41%-0.20%-2.29%+0.81%-9.84%UTHRUnited Therapeutics-0.34%-0.62%-0.12%-3.37%+83.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVONovo Nordisk A/S 2.17Hold$65.5632.48% UpsidePLTRPalantir Technologies 2.57Moderate Buy$190.8550.52% UpsideUTHRUnited Therapeutics 2.83Moderate Buy$644.8217.87% UpsideCurrent Analyst Ratings BreakdownLatest PLTR, NVO, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2026UTHRUnited Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$620.00 ➝ $613.007/7/2026UTHRUnited Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$701.00 ➝ $704.007/6/2026NVONovo Nordisk A/S HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/2/2026PLTRPalantir Technologies DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$165.00 ➝ $175.006/29/2026PLTRPalantir TechnologiesPresident CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$25.50 ➝ $133.006/19/2026NVONovo Nordisk A/S Nordea Equity ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy6/16/2026PLTRPalantir Technologies BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderperform6/16/2026PLTRPalantir Technologies BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold6/16/2026PLTRPalantir Technologies BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral6/16/2026PLTRPalantir Technologies WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform6/16/2026PLTRPalantir Technologies UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy(Data available from 7/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVONovo Nordisk A/S$46.80B4.72$4.74 per share10.43$6.58 per share7.52PLTRPalantir Technologies$4.48B67.92$0.66 per share191.48$3.13 per share40.51UTHRUnited Therapeutics$3.18B7.30$32.54 per share16.81$164.81 per share3.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVONovo Nordisk A/S$15.51B$4.2611.6215.134.4637.23%63.31%22.19%8/5/2026 (Estimated)PLTRPalantir Technologies$1.63B$0.89142.4676.382.1143.67%28.34%23.57%8/3/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0920.1917.641.8240.62%19.24%17.25%7/29/2026 (Estimated)Latest PLTR, NVO, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026NVONovo Nordisk A/S$0.82N/AN/AN/A$10.97 billionN/A8/3/2026Q2 2026PLTRPalantir Technologies$0.35N/AN/AN/A$1.81 billionN/A7/29/2026Q2 2026UTHRUnited Therapeutics$6.97N/AN/AN/A$807.05 millionN/A5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 million5/4/2026Q1 2026PLTRPalantir Technologies$0.2774$0.33+$0.0526$0.34$1.54 billion$1.63 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNVONovo Nordisk A/S$1.753.54%+21.74%41.08%N/APLTRPalantir TechnologiesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVONovo Nordisk A/S0.590.790.56PLTRPalantir TechnologiesN/A6.916.91UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVONovo Nordisk A/S11.54%PLTRPalantir Technologies45.65%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipNVONovo Nordisk A/S0.07%PLTRPalantir Technologies9.53%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionablePLTRPalantir Technologies4,4292.40 billion2.17 billionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionablePLTR, NVO, and UTHR HeadlinesRecent News About These CompaniesInsider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 325 Shares of Stock57 minutes ago | marketbeat.comBank of America Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $613.003 hours ago | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $5,255,115.00 in StockJuly 10 at 5:51 AM | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 SharesJuly 9 at 5:06 PM | marketbeat.comUnited Therapeutics Stock Rises 14% YTD: Here's What You Need to KnowJuly 9 at 3:30 PM | zacks.comIs United Therapeutics Corporation (UTHR) Stock a Long-Term Opportunity in Organ Transplant Innovation?July 8 at 3:51 PM | insidermonkey.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockJuly 8 at 5:21 AM | insidertrades.comUnited Therapeutics acquires Massachusetts biotech companyJuly 7 at 6:38 PM | ncbiotech.orgNUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $704.00July 7 at 12:47 PM | marketbeat.comUnited Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling BuyJuly 6, 2026 | seekingalpha.comUnited Therapeutics Vs. Regencell Bioscience: I Choose Profits Over PromisesJuly 6, 2026 | seekingalpha.comHsbc Holdings PLC Sells 12,743 Shares of United Therapeutics Corporation $UTHRJuly 6, 2026 | marketbeat.comStrs Ohio Increases Stake in United Therapeutics Corporation $UTHRJuly 5, 2026 | marketbeat.comSimplify Asset Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHRJuly 4, 2026 | marketbeat.comMartine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) StockJuly 4, 2026 | americanbankingnews.comFjarde AP Fonden Fourth Swedish National Pension Fund Has $24.03 Million Stock Holdings in United Therapeutics Corporation $UTHRJuly 4, 2026 | marketbeat.comIFM Investors Pty Ltd Acquires Shares of 8,878 United Therapeutics Corporation $UTHRJuly 4, 2026 | marketbeat.comUnited Thera acquires Thymmune for $140 millionJuly 3, 2026 | thepharmaletter.comTUTHR Strengthens Regenerative Medicine Platform With Thymmune DealJuly 3, 2026 | zacks.comUnited Therapeutics (NASDAQ:UTHR) EVP Sells $4,586,248.00 in StockJuly 3, 2026 | insidertrades.comUnited Therapeutics Corporation (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from AnalystsJuly 3, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe AI Trade Is Getting Harder to Pick, But These 3 ETFs Take a Different RouteBy Jessica Mitacek | June 18, 2026Palantir’s Valuation Problem Just Met 2 New Growth CatalystsBy Chris Markoch | June 26, 2026Why Palantir’s Google Cloud Deal Could Change the DebateBy Chris Markoch | June 19, 2026MarketBeat Week in Review – 06/29 - 07/03By Chris Markoch | July 4, 2026Palantir's CEO Just Called Out OpenAI and AnthropicBy Chris Markoch | July 7, 2026PLTR, NVO, and UTHR Company DescriptionsNovo Nordisk A/S NYSE:NVO$49.49 +0.61 (+1.24%) Closing price 03:59 PM EasternExtended Trading$49.42 -0.06 (-0.13%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.Palantir Technologies NASDAQ:PLTR$126.79 -2.25 (-1.74%) Closing price 04:00 PM EasternExtended Trading$126.58 -0.21 (-0.16%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates under the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.United Therapeutics NASDAQ:UTHR$547.06 -5.42 (-0.98%) Closing price 04:00 PM EasternExtended Trading$546.50 -0.56 (-0.10%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab’s Stock Drop Comes With a Bullish Twist Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth PepsiCo’s Dividend Could Turn Patience Into Real Profit Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
